|
|
 |
|
Viewing report
|
|
|
|
All Change in the US Pharma Market?
Espicom Business Intelligence Ltd, June 2008, Pages: 186
Foreword
EXECUTIVE SUMMARY
Industry Overview
Branded company sales overview
Leading Originator Companies, Global Pharmaceutical Revenues, 2006-07 (US$ millions)
Exposure to generics
% of Global Revenues Likely to Face Generic Competition, 2008-12
Branded defence strategies
Incremental innovation
Extended-release formulations
Second-generation products
Citizen petitions
Deals with generic companies
Authorised generics
Biologics
Leading Originator Companies, PHSA Biologic Revenues 2007
FDCA biologics
Generic Approvals and Launches
Pharmaceutical Products Estimated to Face Widespread Generic Competition by 2012
Pharmaceutical Products Estimated to Face Limited Generic Competition by 2012
Pharmaceutical Products Estimated to Face No Generic Competition by 2012
Biologic Products: No Generic Competition to 2012
2007 Global Revenues Subject to Generic Competition by 2012 (US$ millions)
Generic launches at risk?
Summary of at risk? US Generic Launches, 2006-08
Research-Based Company Profiles
Abbott Laboratories
Sales Intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Biaxin
Depakote/Depakote ER
Humira
Kaletra
Omnicef
The Rise of Generics; Drugs at Risk & Defence Strategies
Synthroid
Tricor
A mgen
Sales Intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
US Product Sales Data, 2006-07 (US$ millions)
Aranesp
Epogen
Neulasta
Neupogen
Enbrel
Sensipar
Vectibix
AstraZeneca
Sales Intro
Exposure to generics 2008-12
Defence Strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
US Product Sales Data, 2006-07 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Arimidex
Atacand
Casodex
Crestor
Nexium
Prilosec
Pulmicort
Seroquel
Toprol XL
Zoladex
Zomig
Boehringer Ingelheim
Sales Intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (euros millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (euro millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Aggrenox
Combivent
Flomax
Micardis
Mirapex
Mobic
Spiriva
Bristol-Myers Squibb
Sales Intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
US Product Sales Data, 2006-07 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (£ billions)
2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Abilify
Avapro/Avalide
Baraclude
Erbitux
Orencia
Plavix
Pravachol
Reyataz
Sprycel
Sustiva
Eli Lilly
Sales Intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
US Product Sales Data, 2006-07 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Alimta
Byetta
Cialis
Cymbalta
Evista
Forteo
Gemzar
Humatrope
Strattera
Zyprexa
Insulin products
GlaxoSmithKline
Sales Intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (£ millions)
US Product Sales Data, 2006-07 (£ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (£ billions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (£ billions)
2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Advair Diskus
Augmentin
Avandia
Avodart
Combivir
Coreg
Epzicom
Flonase
Flovent
Imitrex
Lamictal
Paxil
Requip
Trizivir
Valtrex
Wellbutrin
Zofran
Johnson & Johnson
Sales intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Aciphex
Concerta
Duragesic
Levaquin
Procrit
Remicade
Risperdal
Topamax
Merck & Co
Sales intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Cancidas
Cozaar
Emend
Fosamax
Januvia
Maxalt
Primaxin
Proscar/Propecia
Singulair
Trusopt/Cosopt
Zocor
Novartis
Sales intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
US Product Sales Data, 2006-07 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Diovan
Exelon
Famvir
Femara
Focalin
Gleevec
Lamisil
Lescol XL
Lotrel
Sandostatin
Trileptal
Zometa
Pfizer
Sales Intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
2007 Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
2007 Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Aricept
Aromasin
Caduet
Camptosar
Cardura
Celebrex
Chantix
Detrol/Detrol LA
Genotropin
Geodon Oral
Lipitor
Lyrica
Neurontin
Norvasc
Relpax
Sutent
Vfend
Viagra/Revatio
Xalatan
Zithromax
Zoloft
Zyrtec
Zyvox
Roche
Sales intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (CHF millions)
US Product Sales Data, 2006-07 (CHF millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (CHF millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (CHF millions)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Avastin
Boniva
CellCept
Herceptin
Kytril
Lucentis
Nutropin
Pegasys
Rituxan
Tamiflu
Tarceva
Valcyte
Xeloda
Xenical
Xolair
Sanofi Aventis
Sales intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (euro millions)
US Product Sales Data, 2006-07 (euro millions)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (euros millions)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Actonel
Allegra
Amaryl
Ambien
Avapro
Copaxone
Deprocon
Eloxatine
Lantus
Lovenox
Nasacort
Plavix
Taxotere
Altace
Uroxatral
Wyeth
Sales intro
Exposure to generics 2008-12
Defence strategies
Product Summary, 2006-2012
Summary of Products Reviewed
Summary by Year
Global Product Sales Data, 2006-07 (US$ millions)
US Product Sales Data, 2006-07 (US$ millions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (£ billions)
2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
Effexor
The Rise of Generics; Drugs at Risk & Defence Strategies
Prevnar
Protonix
Zosyn/Tazocin
Tygacil
Appendix: Overview of the generic application and approval system
Appendix 1: ANDA Approvals
ANDA Approvals, 2002-08
Customers who bought this item also bought
Mobile TV Business Models, Technologies and Markets 2008-12
Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition
Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition
GenericHandbook - A Guide to the Generic Drug Industry in the US
Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition
The World Generic Market Report 2008
Injectable Generic Drugs: Prospects & Opportunities to 2013
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Opportunities and Challenges for Bioequivalent Generic Drugs in Brazil
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs
Emerging Opportunities in Controlled-Release Generic Drugs
Forecast Insight: Migraine - Generic Incursion Inhibits Market Growth
|
|
|
|
